文献速递白血病造血干细胞移植与细胞治疗

第三方CAR修饰外周血NK细胞过继治疗B细胞前体急性淋巴细胞白血病

Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2019-11-19

本研究开发了一种无饲养层培养方法,对外周血来源NK细胞进行逆转录病毒转导,表达靶向CD19的第二代CAR。CAR.CD19-NK细胞对CD19+细胞系和B-ALL患者原代母细胞的抗白血病活性高于未修饰NK细胞,动物模型中抗白血病活性与CAR-T细胞相当且异种移植毒性更低。

要点

  • 无饲养层扩增并基因修饰外周血NK细胞可行,支持「现货型」免疫基因治疗
  • CAR.CD19-NK对CD19+细胞系及B-ALL原代母细胞活性高于未修饰NK细胞
  • 动物模型中抗白血病活性与CAR-T相当,异种移植毒性更低

核心结论

  • 无饲养层扩增的基因修饰外周血NK细胞可用于有效的「现货型」免疫基因治疗,其先天同种异体反应性可安全增强异体细胞治疗。

研究设计与样本

  • 开发无饲养层培养方法,对外周血来源NK细胞进行逆转录病毒转导,表达靶向CD19的第二代CAR,并在体外及动物模型中评估抗白血病活性。

主要发现

  • CAR表达在不同NK细胞亚群中均得到证实。
  • CAR.CD19-NK细胞对CD19+细胞系和B-ALL患者原代母细胞的抗白血病活性高于未修饰NK细胞。
  • 动物模型数据显示CAR.CD19-NK细胞的抗白血病活性与CAR-T细胞相当,且异种移植毒性更低。

临床怎么用

  • 支持无饲养层扩增、基因修饰的外周血NK细胞作为「现货型」异体细胞治疗候选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We developed an innovative and efficient, feeder-free culture method to genetically modify and expand peripheral blood-derived NK cells with high proliferative capacity, while preserving the responsiveness of their native activating receptors. Activated peripheral blood NK cells were efficiently transduced by a retroviral vector, carrying a second-generation CAR targeting CD19. CAR expression was demonstrated across the different NK-cell subsets. CAR.CD19-NK cells display higher antileukemic activity toward CD19+ cell lines and primary blasts obtained from patients with B-cell precursor ALL compared with unmodified NK cells. In vivo animal model data showed that the antileukemia activity of CAR.CD19-NK cell is superimposable to that of CAR-T cells, with a lower xenograft toxicity profile. These data support the feasibility of generating feeder-free expanded, genetically modified peripheral blood NK cells for effective "off-the-shelf" immuno-gene-therapy, while their innate alloreactivity can be safely harnessed to potentiate allogeneic cell therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Quintarelli C, Sivori S, Caruso S, et al. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2019. PMID: 31745215. doi:10.1038/s41375-019-0613-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。